| Literature DB >> 25924850 |
Lijuan Sun1,2,3, Bodu Liu4,5, Zhaoyu Lin6,7, Yandan Yao8,9, Yanyang Chen10, Yang Li11, Jianing Chen12,13, Dongsheng Yu14, Zhangui Tang15, Bosheng Wang16, Shuguang Zeng17, Song Fan18,19, Youyuan Wang20,21, Yilin Li22, Erwei Song23,24,25, Jinsong Li26,27,28.
Abstract
BACKGROUND: Salivary Adenoid cystic carcinoma (SACC) patients with local invasion and lung metastasis are often resistant to conventional therapy such as operation, chemotherapy and radiotherapy. To explore the underling mechanisms, we studied the roles of miRNA in regulating invasiveness of SACC cells.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25924850 PMCID: PMC4423101 DOI: 10.1186/s12943-015-0344-y
Source DB: PubMed Journal: Mol Cancer ISSN: 1476-4598 Impact factor: 27.401
Figure 1Ectopic expression of miR-320a inhibits the invasiveness of salivary adenoid cystic carcinoma cells. (A) miR-320a expression in SACC cells was determined by qRT-PCR analysis. **P < 0.01 vs. parental SACC cells. ## P < 0.01 vs. mock transfection. U6 was used as an internal control. Adhesion assays (B) and transwell assays (C, D) showed that adhesion, invasion and migration of ACCM and SACC-LM cells were inhibited by miR-320a mimics (100×). (E) Quantification of adhesive, invasive and migratory cells assessed by adhesion assays and transwell assays. *P < 0.05; **P < 0.01 vs. mock.
Figure 2ITGB3 is an miR-320a target gene. (A) Target sequence of miR-320a in ITGB3 3′-UTR predicted by TargetScan, as well as the mutated sequence. (B) Luciferase reporter assays were performed in ACCM and SACC-LM cells co-transfected with miR-320a-mimics and reporter vectors carrying a ITGB3 3′-UTR with a wild-type (ITGB3 3′-UTR) or mutated miR-320a (ITGB3 3′-UTR mut) response element. *P < 0.05 vs. mock transfection. (C) Integrin β3 expression, as well as FAK and Src phosphorylation, was assessed using western blot analysis. β-actin was used as an internal control. (D) Colocalization of integrin β3 and the cytoskeletal protein actin was illustrated by immunofluorescence staining. Nuclei: blue, scale bar: 10 μm.
Figure 3miR-320a inhibits the invasiveness of SACC cells by targeting ITGB3. (A) Integrin β3 expression and FAK and Src phosphorylation were determined by western blot analysis in ACCM cells transfected with miR-320a mimics alone or in combination with either pcDNA 3.1+ (Vector) or pcDNA 3.1+ containing a wild-type (ITGB3) or mutant ITGB3 expression cassette of the miR-320a (ITGB3 mut) response element. β-actin was used as an internal control. Adhesion, invasion and migration of ACCM cells were assessed using adhesion assays (B) and transwell assays (C, D) (100x). (E) Quantification of adhesive, invasive and migratory ACCM cells. *P < 0.05; **P < 0.01; ***P < 0.001 vs. vector.
Figure 4Ectopic expression of miR-320a inhibits ACCM xenograft metastasis in BALB/c-nu mice. (A) Whole-body luminal imaging was performed in mice inoculated with ACCM stably expressing the luciferase gene. Luminal images (B) and HE staining (C) of paraffin sections (200×) of the lungs (upper) and livers (lower) of the tumor-bearing mice. (D) Mean ± SD wet lung weight of tumor-bearing mice (n = 8/group). (E) Expression of human HPRT mRNA relative to mouse 18S rRNA in the lungs and livers of the tumor-bearing mice was determined by qRT-PCR analysis. **P < 0.01 vs. ACC2 cells. ## P < 0.01 vs. EmGFP transfection.
Figure 5miR-320a downregulation correlates with metastasis and poor patient survival in SACCs. (A) In situ hybridization for miR-320a and immunohistochemical staining for integrin β3 in primary SACCs with metastasis vs. those without metastasis (200×). Quantification of miR-320a and integrin β3 expression in primary SACC samples from the affiliated hospitals of Sun Yat-sen University (B) or from the affiliated hospitals of Central South University (C). ***P < 0.001. Kaplan-Meier curves for SACC patients from the affiliated hospitals of Sun Yat-sen University comparing miR-320a expression and metastasis (D) or miR-320a expression and survival (E) was analyzed by the log rank test. Kaplan-Meier curves for SACC patients from the affiliated hospitals of Central South University comparing miR-320a expression and metastasis (F) or miR-320a expression and survival (G). The median value was used to distinguish high expression and low expression.
Correlation among clinicopathologic status and the expression of miR-320a or integrin β3 in SACC patients
|
| ||||||
|---|---|---|---|---|---|---|
|
|
|
| ||||
|
|
|
|
|
|
| |
| Sex | 0.905 | 0.097 | ||||
| Male | 83 (61.9) | 51 (38.1) | 45 (33.6) | 89 (66.4) | ||
| Female | 106 (63.1) | 62 (36.9) | 73 (43.5) | 95 (56.5) | ||
| Age | 0.153 | 0.814 | ||||
| <50 | 82 (58.2) | 59 (41.8) | 54 (38.3) | 87 (61.7) | ||
| ≥50 | 107 (66.5) | 54 (33.5) | 64 (39.8) | 97 (60.2) | ||
| Tumor Size | 0.801 | 0.319 | ||||
| T1-2 | 125 (61.9) | 77 (38.1) | 83 (41.1) | 119 (58.9) | ||
| T3-4 | 64 (64.0) | 36 (36.0) | 35 (35.0) | 65 (65.0) | ||
| Node metastasis | 0.029 | 0.032 | ||||
| N0 | 154 (59.9) | 103 (40.1) | 107 (41.6) | 150 (58.4) | ||
| N1 | 35 (77.8) | 10 (22.2) | 11 (24.4) | 34 (75.6) | ||
| TNM stage | 0.074 | 0.044 | ||||
| I-II | 95 (57.9) | 69 (42.1) | 73 (44.5) | 91 (55.5) | ||
| III-IV | 94 (68.1) | 44 (31.9) | 45 (32.6) | 93 (67.4) | ||
| Distant Metastasis | <0.001 | 0.001 | ||||
| No | 90 (52.3) | 82 (47.7) | 81 (47.1) | 91 (52.9) | ||
| Yes | 99 (76.2) | 31 (23.8) | 37 (28.5) | 93 (71.5) | ||
| Status | 0.002 | 0.009 | ||||
| Survival | 84 (54.2) | 71 (45.8) | 72(46.5) | 83 (53.5) | ||
| Death | 105 (71.4) | 42 (28.6) | 46(31.3) | 101 (68.7) | ||
|
| ||||||
| Sex | 0.496 | 0.865 | ||||
| Male | 53 (66.2) | 27 (33.8) | 29 (36.2) | 51 (63.8) | ||
| Female | 41 (60.3) | 27 (39.7) | 26 (38.2) | 42 (61.8) | ||
| Age | 0.170 | 0.609 | ||||
| <50 | 47 (58.0) | 34 (42.0) | 32 (39.5) | 49 (60.5) | ||
| ≥50 | 47 (70.1) | 20 (29.9) | 23 (34.3) | 44 (65.7) | ||
| Tumor Size | 0.601 | 0.861 | ||||
| T1-2 | 60 (65.2) | 32 (34.8) | 35 (38.0) | 57 (62.0) | ||
| T3-4 | 34 (60.7) | 22 (39.3) | 20 (35.7) | 36 (64.3) | ||
| Node metastasis | 0.811 | 0.469 | ||||
| N0 | 80 (63.0) | 47 (37.0) | 49 (38.6) | 78 (61.4) | ||
| N1-N2 | 14 (66.7) | 7 (33.3) | 6 (28.6) | 15 (71.4) | ||
| TNM stage | 0.392 | 0.608 | ||||
| I-II | 56 (66.7) | 28 (33.3) | 33 (39.3) | 51 (60.7) | ||
| III-IV | 38 (59.4) | 26 (40.6) | 22 (34.4) | 42 (65.6) | ||
| Distant Metastasis | 0.001 | 0.004 | ||||
| No | 42 (51.2) | 40 (48.8) | 39 (47.6) | 43 (52.4) | ||
| Yes | 52 (78.8) | 14 (21.2) | 16 (24.2) | 50 (75.8) | ||
| Status | 0.004 | 0.017 | ||||
| Survival | 37 (51.4) | 35 (48.6) | 34 (47.2) | 38 (52.8) | ||
| Death | 57 (75.0) | 19 (25.0) | 21 (27.6) | 55 (72.4) | ||